Hematology
Conference Coverage
Lenalidomide may reduce risk of progression from SMM to MM
At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66...
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
Conference Coverage
Lymphoma rate in RA patients is falling
MAUI, HAWAII – “Does this reflect a change in the practice of rheumatology? I think it does,” said John J. Cush, MD.
News
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Conference Coverage
Complementary medicine use common among patients on TKIs
GLASGOW – A survey of chronic myeloid leukemia patients taking tyrosine kinase inhibitors (TKIs) revealed that more than one-third were taking...
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Conference Coverage
CAR T cells home in on HER2 in advanced sarcomas
ATLANTA – A teenage girl with advanced osteosarcoma has had a durable complete remission after receiving CAR T cells targeted to HER2.
Conference Coverage
FDA panel leans toward more robust breast implant surveillance
SILVER SPRING, MD. – Amid concern over two breast implant complications – anaplastic large cell lymphoma and autoimmune symptoms – an FDA panel...
